Ultragenyx Pharmaceutical’s (RARE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research report report published on Monday,Benzinga reports. They currently have a $50.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q3 2026 earnings at $0.75 EPS, Q4 2026 earnings at $0.78 EPS, FY2026 earnings at ($1.18) EPS, Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.91 EPS, Q3 2027 earnings at $1.25 EPS, Q4 2027 earnings at $2.27 EPS and FY2027 earnings at $4.50 EPS.

A number of other brokerages have also recently issued reports on RARE. Wells Fargo & Company reduced their price objective on Ultragenyx Pharmaceutical from $47.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings upgraded Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Wall Street Zen upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Wedbush decreased their price target on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Finally, Barclays decreased their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $57.82.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE opened at $26.86 on Monday. Ultragenyx Pharmaceutical has a 1 year low of $18.29 and a 1 year high of $39.89. The stock has a 50 day simple moving average of $28.16 and a two-hundred day simple moving average of $24.90. The firm has a market cap of $2.65 billion, a P/E ratio of -4.60 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.32. The firm had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business’s revenue was up 28.5% compared to the same quarter last year. During the same period last year, the firm posted ($1.17) earnings per share. On average, equities analysts anticipate that Ultragenyx Pharmaceutical will post -4.08 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Shehnaaz Suliman sold 5,740 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $25.12, for a total transaction of $144,188.80. Following the transaction, the director directly owned 27,951 shares of the company’s stock, valued at approximately $702,129.12. The trade was a 17.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the transaction, the executive vice president owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 14,292 shares of company stock valued at $351,644 in the last 90 days. 5.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of RARE. Parallel Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,440 shares during the period. Leonteq Securities AG boosted its position in shares of Ultragenyx Pharmaceutical by 288.5% during the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,333 shares in the last quarter. Versant Capital Management Inc grew its stake in Ultragenyx Pharmaceutical by 662.9% in the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,001 shares during the period. Danske Bank A S purchased a new stake in Ultragenyx Pharmaceutical in the third quarter worth $39,000. Finally, EverSource Wealth Advisors LLC grew its stake in Ultragenyx Pharmaceutical by 573.0% in the first quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,845 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Key Headlines Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright sharply raised its Q3 2026 EPS estimate to $0.75 from a loss of $0.84 per share and increased its Q4 2026 forecast to $0.78 from a loss of $0.35. The changes suggest expectations for a faster-than-anticipated improvement in Ultragenyx’s profitability. Ultragenyx Pharmaceutical Earns Buy Rating from HC Wainwright
• Neutral Sentiment: HC Wainwright maintained its Buy rating and $50 price target, well above the stock’s recent trading level. Separately, a brokerage consensus cited a price target of approximately $57.82, indicating substantial potential upside if the company executes on its pipeline and reaches profitability. Brokerages Set Ultragenyx Pharmaceutical Price Target
• Neutral Sentiment: Ultragenyx and Baylor Research Institute reportedly settled a patent lawsuit involving generic competition to DOJOLVI. The settlement removes some litigation uncertainty, but the financial and commercial terms were not provided, limiting the immediate valuation impact. Ultragenyx and Baylor Settle DOJOLVI Patent Lawsuit
• Negative Sentiment: HC Wainwright lowered its 2027 EPS estimates across the board: Q1 to $0.06 from $0.27, Q2 to $0.91 from $1.18, Q3 to $1.25 from $1.54, Q4 to $2.27 from $2.63, and full-year 2027 to $4.50 from $5.61. These reductions weigh on longer-term earnings expectations, even though the analyst remains bullish.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.